NCT05316935View on ClinicalTrials.gov

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2027

Conditions
Endometrial NeoplasmsAtypical Endometrial HyperplasiaProgesterone Resistance
Interventions
DRUG

GnRHa

Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.

DRUG

Letrozole 2.5mg

2.5mg po qd and no more than 24 weeks

DRUG

Diane-35

Periodic use. Patients will receive one pill po qd for 21 days, and next period should be started after 7 days.

DRUG

MET

500mg po tid

Trial Locations (2)

200011

RECRUITING

Obstetrics and Gynecology Hospital, Fudan University, Shanghai

Unknown

RECRUITING

Tenth People's Hospital of Tongji University, Shanghai

All Listed Sponsors
lead

Xiaojun Chen

OTHER